Semaglutide medication names: what each one is actually licensed for

You searched the name but found four products: here is what separates them

Picture this: you read about semaglutide in a Sunday supplement, searched online and came back with four different names. That confusion is genuinely common, and it matters, because the name attached to a medicine in the UK is not just a marketing choice. It reflects a specific regulatory approval, a specific dose schedule and a specific patient group. Getting the wrong one is not just ineffective; for a prescription-only medicine, it is unsafe.

Start with the shared biology. Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone involved in appetite regulation and blood-sugar control, slowing gastric emptying and reducing hunger signals. That single mechanism has been developed into two delivery routes (injection and tablet) and licensed for two distinct clinical purposes (weight management and type 2 diabetes). The medication class is the same across all four products; the licensed use is not. The NHS semaglutide medicines page gives a clear overview of how these products relate to one another and what each is prescribed for.

Knowing the right name before you speak to a prescriber helps you ask the right question and protects you from purchasing something that was never authorised for your goal.

Wegovy injection: the licensed weight-management brand, and its new higher dose

Wegovy is the brand name for the weekly semaglutide injection designed specifically for weight management. Made by Novo Nordisk, it is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition. The standard titration runs from 0.25 mg upward through 0.5, 1.0 and 1.7 mg to a 2.4 mg maintenance dose, with each step supervised by a prescriber.

In April 2026 the MHRA approved a dedicated 7.2 mg single-dose Wegovy pen, a higher maintenance option with a built-in covered needle that locks after use. Trial data for that dose reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide results. If you want more detail on what the Wegovy medication name means, including the regulatory and clinical reasons behind it, the relevant overview covers the full picture.

NICE has also recommended semaglutide (TA875) for use within specialist weight management services, but only for a maximum of two years and subject to strict eligibility criteria including at least one weight-related comorbidity. NHS waiting lists for that route can be long; a private prescription through a regulated pharmacy is the alternative for those who meet the clinical threshold but not the NHS service criteria.

Ozempic and Rybelsus: semaglutide names that are not licensed for weight loss

Ozempic is semaglutide in pre-filled injection pen format, licensed in the UK for type 2 diabetes. It is not authorised for weight management. The MHRA has been clear on this point, and the NHS reiterates it on its medicines pages. Prescribing Ozempic for weight loss would be off-label, which carries real clinical and supply-chain risks, and widespread off-label demand contributed directly to the shortages that affected people with diabetes who genuinely relied on it.

Rybelsus is oral semaglutide, but again for type 2 diabetes: its 3 mg, 7 mg and 14 mg tablet strengths are the diabetes schedule and have nothing to do with the Wegovy tablet weight-loss programme. Confusing them is easy because the ingredient is identical; the doses and the licensed purpose are not. For anyone researching the various semaglutide brand and generic names, that distinction is the single most important thing to hold onto.

If a seller offers you Ozempic or Rybelsus for weight loss without a prescription, that is a red flag on multiple levels: the product is not licensed for that use, and a sale without clinical assessment would breach UK medicines law. Report suspect sellers at the MHRA's Yellow Card scheme.

Wegovy tablets: the newest semaglutide name, and what sets it apart

On 11 June 2026 the MHRA approved Wegovy in tablet form, the first oral GLP-1 medicine licensed for weight management in the UK, and the first in Europe. It is the same active ingredient as the injection, but reformulated with an absorption enhancer called SNAC so it can survive the digestive process and reach the bloodstream from the gut.

The dose schedule is distinct from both the injection and the diabetes tablets: it starts at 1.5 mg daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. Crucially, those are Wegovy tablet doses only, the 3 mg and 7 mg figures you might see elsewhere belong to Rybelsus. The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, and you need to wait at least 30 minutes before any food, coffee or other oral medicines, including anyone who should be aware of how semaglutide interacts with ADHD medication before starting treatment. No refrigeration is required, which makes it notably more practical for travel.

Phase-3 trial data (OASIS 4, 64 weeks) showed around 13.6% average weight loss versus roughly 2.4% for placebo. Among participants who adhered fully to treatment, average loss was closer to 17%, though that figure applies specifically to the fully-adherent group, not the trial as a whole. For a fuller look at what Wegovy involves and how it compares with other options, our treatment pages go into the detail a quick search rarely provides. If you are ready to find out which form of semaglutide, if any, fits your clinical picture, you can check your eligibility through a free consultation with one of our GPhC-registered prescribers.